Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer

Introduction: The mutation rate of T790M might change the effective therapeutic sequence of EGFR tyrosine kinase inhibitors (TKIs). This simulation estimates the T790M positivity rate required for first-line first- or second-generation EGFR TKI to exceed overall progression-free survival (PFS) of fi...

Olles dieđut

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkkit:	Naoki Haratake, MD, PhD, Toshihiro Misumi, PhD, Takeharu Yamanaka, PhD, Takashi Seto, MD, PhD
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2020-11-01
Ráidu:	JTO Clinical and Research Reports
Fáttát:	Non–small cell lung cancer EGFR Sequential treatment Rebiopsy T790M
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2666364320301089
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer

Geahča maid